[Definitive or neo-adjuvant chemoradiation in esophageal carcinoma?] / Cancer de l'Åsophage : radio-chimiothérapie exclusive ou préopératoire ?
Cancer Radiother
; 23(6-7): 716-719, 2019 Oct.
Article
in Fr
| MEDLINE
| ID: mdl-31421997
ABSTRACT
Management of resectable esophageal carcinoma is based on a multimodal treatment associating neo-adjuvant chemoradiation before surgery. This therapeutic sequence allows a disease-free survival rate at 2 years around 45% but remains associated with a high post-operative morbidity. In case of definitive chemoradiotherapy, the dose delivered to the macroscopic disease is a controversial topic since decades and the prognosis of patients treated in this setting at the dose of 50Gy remains poor. This article proposes a review of the main published data and the ongoing studies related to the management of these patients.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Esophageal Neoplasms
/
Carcinoma
/
Neoadjuvant Therapy
/
Chemoradiotherapy, Adjuvant
Limits:
Humans
Language:
Fr
Journal:
Cancer Radiother
Journal subject:
NEOPLASIAS
/
RADIOTERAPIA
Year:
2019
Type:
Article